Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pixatimod - Zucero Therapeutics

Drug Profile

Pixatimod - Zucero Therapeutics

Alternative Names: PG-545

Latest Information Update: 14 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Progen Pharmaceuticals
  • Developer Bristol-Myers Squibb; Medigen Biotechnology Corporation; Progen Pharmaceuticals Limited; Zucero Therapeutics
  • Class Antineoplastics; Glycosaminoglycans; Oligosaccharides; Small molecules
  • Mechanism of Action Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours
  • Preclinical Liver cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 13 Nov 2018 Preliminary efficacy, adverse events and pharmacodynamics data from a phase Ib trial in Solid tumours presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018)
  • 24 Oct 2017 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (ACTRN12617001573347)
  • 24 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia (IV) (ACTRN12617001573347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top